<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">Korean J. Intern. Med</journal-id><journal-title-group><journal-title>The Korean Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">1226-3303</issn><issn pub-type="epub">2005-6648</issn><publisher><publisher-name>Korean Association of Internal Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12760265</article-id><article-id pub-id-type="pmc">4531596</article-id><article-id pub-id-type="doi">10.3904/kjim.2003.18.1.29</article-id><article-id pub-id-type="publisher-id">kjim-18-1-29-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Role of C-Reactive Protein on the Long-Term Clinical Outcome after Primary or Rescue Percutaneous Coronary Intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Young Joon</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Myung Ho</given-names></name><degrees>M.D., Ph.D.</degrees><xref ref-type="corresp" rid="c1-kjim-18-1-29-5"/></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Ok Young</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Weon</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ju Han</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Young Keun</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Jeong Gwan</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Byoung Hee</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Suh</surname><given-names>Soon Pal</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong Chun</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sang Hyung</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Jung Chaee</given-names></name><degrees>M.D., Ph.D.</degrees></contrib><aff id="af1-kjim-18-1-29-5">The Heart Center of Chonnam National University Hospital, The Research Institute of Medical Sciences, Chonnam National University, Gwangju, Korea</aff></contrib-group><author-notes><corresp id="c1-kjim-18-1-29-5">Correspondence to : Myung Ho Jeong, M.D., Ph.D., FACC, FSCAI, Chief of Cardiovascular Medicine, Director of Cardiac Catheterization Laboratory, The Heart Center of Chonnam National University Hospital, 8 Hak-dong, Dong-gu, Gwangju 501-757, Korea. E-mail: <email>myungho@chollian.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2003</year></pub-date><volume>18</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2002</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2003</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2003 The Korean Association of Internal Medicine</copyright-statement><copyright-year>2003</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>We examined the clinical and angiographic outcomes, success rate of the percutaneous coronary intervention (PCI) and long-term survival rate after primary or rescue PCI in patients with acute myocardial infarction (AMI) according to the level of the C-Reactive Protein (CRP) on admission.</p></sec><sec><title>Methods</title><p>Two hundred and eight consecutive patients with AMI who underwent primary or rescue PCI between 1997 and 1999 at Chonnam National University Hospital were divided into two groups: Group I (n=86, 59.9 &#x000b1;9.3 years, male 74.4%) with a normal CRP (&#x0003c;1.0 mg/dL, mean value=0.43&#x000b1;0.14 mg/dL) on admission and Group II (n=122, 59.1&#x000b1;10.4 years, male 83.6%) with an elevated CRP (&#x02265;=1.0 mg/dL, mean value=3.50&#x000b1;0.93 mg/dL) on admission.</p></sec><sec><title>Results</title><p>There were no significant differences in the baseline characteristics noted between the two groups. The incidence of cardiogenic shock was higher in Group II than in Group I (Group I; 3/86, 3.5% vs. Group II; 15/122, 12.3%, <italic>p</italic>=0.026). The coronary angiographic findings did not differ between the two groups. The ejection fraction and Thrombolysis In Myocardial Infarction flow grade improved after PCI in both groups. The primary success rate of PCI was 94.2% (81/86) in Group I and 95.1% (116/122) in Group II (<italic>p</italic>=0.776). The survival rates for Group I were 97.7%, 97.7% and 96.5%, and those for Group II were 91.8%, 91.0% and 86.9% at 1, 6 and 12 months, respectively (<italic>p</italic>=0.043 at 1 month, <italic>p</italic>=0.040 at 6 months, <italic>p</italic>=0.018 at 12 months).</p></sec><sec><title>Conclusion</title><p>A high incidence of cardiogenic shock and worse long-term survival after PCI are observed in AMI patients with an elevated CRP.</p></sec></abstract><kwd-group><kwd>Myocardial infarction</kwd><kwd>Angioplasty</kwd><kwd>Shock</kwd><kwd>Prognosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Percutaneous coronary intervention (PCI) has been introduced as one of the effective methods in the treatment of acute myocardial infarction (AMI), and an understanding of the pathophysiologic changes involved in the underlying coronary arterial lesion after PCI may be important<sup><xref rid="b1-kjim-18-1-29-5" ref-type="bibr">1</xref>, <xref rid="b2-kjim-18-1-29-5" ref-type="bibr">2</xref>)</sup>. An inflammatory reaction is one of the important pathologic findings in the atheromatous plaque of patients with acute coronary syndrome, and lymphocytes and monocytes/macrophages accumulate at the site of the plaque rupture<sup><xref rid="b3-kjim-18-1-29-5" ref-type="bibr">3</xref>, <xref rid="b4-kjim-18-1-29-5" ref-type="bibr">4</xref>)</sup>.</p><p>One of the acute phase reactants, C-reactive protein (CRP), is synthesized in the liver by stimulation of cytokines, such as interleukin-6, and begins to elevate within 6 hours after stimulation of the liver by cytokine<sup><xref rid="b5-kjim-18-1-29-5" ref-type="bibr">5</xref>, <xref rid="b6-kjim-18-1-29-5" ref-type="bibr">6</xref>)</sup>. The serum level of CRP reflects the overall systemic inflammatory reaction within the body and is a simple and objective index<sup><xref rid="b7-kjim-18-1-29-5" ref-type="bibr">7</xref>)</sup>.</p><p>The level of CRP is closely related to atherosclerosis in coronary, cerebral and peripheral arteries<sup><xref rid="b8-kjim-18-1-29-5" ref-type="bibr">8</xref>)</sup>. An increase in the serum CRP is known to relate with cardiovascular complications, such as sudden cardiac death or AMI<sup><xref rid="b9-kjim-18-1-29-5" ref-type="bibr">9</xref>)</sup>. In the Multiple Risk Factor International Trial (MRFIT), the level of the CRP was significantly related with mortality due to coronary artery diseases<sup><xref rid="b10-kjim-18-1-29-5" ref-type="bibr">10</xref>)</sup>.</p><p>The effects of the initial CRP level on the long-term mortality in patients with AMI, especially after primary or rescue PCI, have not been reported. Our study sought to observe the effects of the serum level of the CRP at the time of admission on the short- and long-term prognosis in patients with AMI after primary or rescue PCI, and the long-term prognosis in patients with AMI after primary or rescue PCI.</p></sec><sec sec-type="methods"><title>METHODS</title><sec sec-type="subjects"><title>1. Subjects</title><p>All consecutive patients with AMI, who were admitted and underwent primary or rescue PCI at The Heart Center of Chonnam National University Hospital between January 1997 and December 1999, were included in this study. All patients had chest pain for a duration of less than 6 hours and prolonged chest pain for more than 30 minutes not responsive to nitroglycerin or ST elevation of more than 1 mV in two or more limb leads or 2 mV in two consecutive precordial leads. Primary PCI was performed in 177 patients (59.4&#x000b1;9.7 years-old, M:F=141:36) and rescue PCI in 31 patients (59.7&#x000b1;11.4 years-old, M:F=25:6). The two hundred and eight patients were divided into two groups; Group I (n=86, 59.9&#x000b1;9.3 years-old, M:F=64:22, CRP less than 1 mg/dL) and Group II (n=122, 59.1&#x000b1;10.4 years-old, M:F=102:20, CRP higher than 1 mg/dL), and the clinical and angiographic characteristics, success rate of the PCI and the one-month, six-month and 12-month mortality were compared retrospectively between the two groups during a one-year clinical follow-up.</p></sec><sec><title>2. Laboratory and angiographic assessments</title><p>A blood sample was obtained on arrival at the emergency room and stored in a refrigerator. The serum level of the CRP was measured by the latex photometric immunoassay method, and 1 mg/dL was set as the cut-off value for the comparison between the high and low groups. The left ventricular ejection fraction was compared by the Simpson method using two-dimensional echocardiography. A coronary angiogram was performed through the femoral or radial arteries. Coronary artery lesions were classified using the American College of Cardiology/American Heart Association system, in which a stenosis of more than 75% defined as a significant lesion<sup><xref rid="b11-kjim-18-1-29-5" ref-type="bibr">11</xref>)</sup>. The lesion location, involved vessel number, lesion characteristics and presence of an intracoronary thrombus on the coronary angiogram were compared between the two groups, and the vessel patency of the infarct-related artery was assessed by the Thrombolysis in Myocardial Infarction (TIMI) flow score<sup><xref rid="b12-kjim-18-1-29-5" ref-type="bibr">12</xref>)</sup>. TIMI 0 was defined as a total occlusion without any distal flow below the lesion, TIMI 1 as trivial distal flow without complete visualization of the entire artery, TIMI 2 as complete visualization of the entire coronary artery with a slow flow rate and TIMI 3 as complete visualization of the entire artery with a normal flow rate. Successful revascularization was defined as a TIMI flow score of more than grade 2 and residual stenosis less than 50%<sup><xref rid="b13-kjim-18-1-29-5" ref-type="bibr">13</xref>)</sup>.</p><p>Rescue PCI was defined as a dilation of the occluded infarct-related artery less than 6 hours after the onset of chest pain in patients with persistent ST segment elevation and persistent chest pain after thrombolytic therapy. Urokinase or tissue plasminogen activator was used for thrombolysis and 100&#x02013;300 mg of aspirin was administered daily. Heparin was administered to maintain an activated partial thromboplastin time of about 2 times above the normal control. After discharge from the hospital, the patients were observed at the out-patient clinic at 4 week intervals, and the cardiovascular mortality was assessed at 1, 6 and 12 months after the PCI. Restenosis was defined as diameter stenosis more than 50% by the Phillips quantitative coronary angiogram analysis system.</p></sec><sec sec-type="methods"><title>3. Statistical analysis</title><p>For the statistical analysis, the unpaired <italic>t</italic>-test, Chi-square test and multiple logistic regression analysis were performed using SPSS-PC 10.0 (Statistical package for the social sciences, SPSS Inc. Chicago, IL, U.S.A.) and MS Windows&#x000ae;, and the results were designated as mean&#x000b1;standard deviation. A value of <italic>p</italic> less than 0.05 was considered as significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec sec-type="intro"><title>1. Clinical characteristics</title><p>The age and sex ratios did not differ between the two groups (<italic>p</italic>=0.599, 0.104 respectively). There were no differences in these risk factors between the two groups (<italic>p</italic>=0.472, 0.373, 0.054 and 0.346, respectively) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>). The incidence of cardiogenic shock was 3 cases in Group I (3.5%) and 15 in Group II (12.3%), and was higher in Group II than in group I (<italic>p</italic>=0.026) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>). The values of Troponin I and T and ESR were higher than those in Group I (<italic>p</italic>&#x0003c;0.001, &#x0003c;0.001 and =0.026, respectively) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>).</p></sec><sec sec-type="intro"><title>2. Coronary angiographic characteristics</title><p>The time interval between the onset of symptoms and arrival at the emergency room, and the interval between the onset of symptoms and the time of the PCI did not differ between the two groups (<italic>p</italic>=0.860 and 0.843, respectively) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>). The number of patients that underwent rescue PCI or primary PCI did not differ between the two groups (<italic>p</italic>=0.747) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>). The number of vessels involved on diagnostic coronary angiography did not differ between the two groups (<italic>p</italic>=0.753) (<xref ref-type="table" rid="t2-kjim-18-1-29-5">Table 2</xref>). The mean number of vessels involved was 1.60&#x000b1;0.71 in group I and 1.54&#x000b1;0.71 in group II. The order of frequency in the number of vessels involved was single vessel disease, two vessel disease and three vessel disease.</p><p>Lesions involving the left anterior descending artery were the most common, but the lesion distribution did not differ between the two groups (<italic>p</italic>=0.642) (<xref ref-type="table" rid="t2-kjim-18-1-29-5">Table 2</xref>). The lesion morphology assessed according to the ACC/AHA classification was not significantly different between the two groups (<italic>p</italic>=0.634) (<xref ref-type="table" rid="t2-kjim-18-1-29-5">Table 2</xref>). An intracoronary thrombus was not different between the two groups (<italic>p</italic>=0.450) (<xref ref-type="table" rid="t2-kjim-18-1-29-5">Table 2</xref>). The mean TIMI flow grade did not differ between the two groups (<italic>p</italic>=0.087) (<xref ref-type="table" rid="t2-kjim-18-1-29-5">Table 2</xref>).</p></sec><sec sec-type="results"><title>3. Results of PCI</title><p>The mean TIMI flow grade represented a significant improvement after the PCI (<italic>p</italic>&#x0003c;0.001) (<xref ref-type="table" rid="t4-kjim-18-1-29-5">Table 4</xref>), and there was no significant difference between the two groups (<italic>p</italic>=0.863) (<xref ref-type="table" rid="t3-kjim-18-1-29-5">Table 3</xref>). The primary success rate resulted in no difference between the two groups (<italic>p</italic>=0.776) (<xref ref-type="table" rid="t3-kjim-18-1-29-5">Table 3</xref>).</p></sec><sec><title>4. Left ventricular ejection fraction</title><p>The ejection fraction measured by two-dimensional echocardiography on admission did not differ between the two groups (<italic>p</italic>=0.673) (<xref ref-type="table" rid="t1-kjim-18-1-29-5">Table 1</xref>). After the PCI, the ejection fraction significantly improved in both groups (<italic>p</italic>&#x0003c;0.001) (<xref ref-type="table" rid="t4-kjim-18-1-29-5">Table 4</xref>).</p></sec><sec><title>5. Major adverse cardiac events and the long-term survival</title><p>The in-hospital death at the time of admission that presented with cardiogenic shock occurred in 2 cases in group I and 7 cases in group II. Major adverse cardiac events were observed in all patients at one, six and twelve months. Restenosis represented a significantly higher occurrence in group II (<italic>p</italic>=0.009) and the number of cases with target lesion revascularization was higher in group II (<italic>p</italic>=0.017) (<xref ref-type="table" rid="t5-kjim-18-1-29-5">Table 5</xref>).</p><p>The survival rate was analyzed during the clinical follow-up at 1, 6 and 12 months after the PCI and the survival rate was significantly lower in group II than in group I for each time period (<italic>p</italic>=0.043, 0.040 and 0.018, respectively) (<xref ref-type="table" rid="t3-kjim-18-1-29-5">Table 3</xref>).</p></sec><sec><title>6. Independent predictive factors for the one-year mortality</title><p>Multiple logistic regression analysis was performed for the prediction of the one-year mortality after primary or rescue PCI. Cardiogenic shock at the time of admission, a CRP higher than 1 mg/dL and an ejection fraction lower than 40% after the PCI were independent risk factors (<italic>p</italic>&#x0003c;0.001, 0.001 and 0.043, respectively), whereas cardiac tropanin-T was a strong albeit not independent predictor indicating a one-year mortality. Age, sex, risk factors for atherosclerosis, target lesion location, involved vessel number and TIMI flow grade were not independent risk factors (<xref ref-type="table" rid="t6-kjim-18-1-29-5">Table 6</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our study demonstrated that the event-free survival was higher in patients with AMI and high CRP after primary or rescue PCI. The mechanism of the inflammatory reaction in acute myocardial infarction has not been clearly elucidated<sup><xref rid="b14-kjim-18-1-29-5" ref-type="bibr">14</xref>)</sup>, but previous reports suggested that the level of CRP is elevated in patients with acute myocardial infarction and that CRP is an important factor for the prediction of the short-and long-term prognosis in acute myocardial infarction<sup><xref rid="b15-kjim-18-1-29-5" ref-type="bibr">15</xref>&#x02013;<xref rid="b18-kjim-18-1-29-5" ref-type="bibr">18</xref>)</sup>. CRP is produced from liver cells stimulated by cytokines, such as interleukin-6 (IL-6), tumor necrosis factor (TNF)-&#x003b1; and interieukin-1 (IL-1), and these kinds of cytokines are released from activated monocytes/macrophages during ischemic insults in patients with an acute myocardial infarction<sup><xref rid="b19-kjim-18-1-29-5" ref-type="bibr">19</xref>)</sup>. A recent study reported that the concentration of IL-6 was closely related to the level of CRP in an acute myocardial infarction<sup><xref rid="b20-kjim-18-1-29-5" ref-type="bibr">20</xref>)</sup>. Our results suggested that elevated CRP could predict poor prognosis even after successful PCI in patients with AMI.</p><p>The level of CRP at the time of admission in patients with an acute myocardial infarction can be used as a useful index for the assessment of the vulnerability of the coronary artery lesion. Tomoda et al.<sup><xref rid="b21-kjim-18-1-29-5" ref-type="bibr">21</xref>)</sup> reported that a level of CRP greater than 0.3 mg/dL in patients with an acute myocardial infarction was related to the restenosis after the primary PCI, restenosis, recurrent myocardial infarction and cardiac death. In contrast, in the patients with a normal CRP on admission, major adverse cardiac events were demonstrated in less than 5% of the patients.</p><p>Our study demonstrated that lower event-free survival at one, six and twelve months after the PCI was observed in patients with a CRP higher than 1 mg/dL. Our preliminary study<sup><xref rid="b22-kjim-18-1-29-5" ref-type="bibr">22</xref>)</sup> showed that the mean value of CRP was elevated in Asian patients with an acute myocardial infarction. Liuzzo et al.<sup><xref rid="b23-kjim-18-1-29-5" ref-type="bibr">23</xref>)</sup> reported that the serum concentration of CRP was elevated after PCI in patients with a high CRP, but not so in patients with a normal baseline CRP or in patients with stable angina. Zebrack et al.<sup><xref rid="b24-kjim-18-1-29-5" ref-type="bibr">24</xref>)</sup> reported that pre-discharge CRP levels are higher after acute myocardial infarction than after unstable angina or stable angina and that CRP is strongly predictive of long-term risk of death or nonfatal acute myocardial infarction for unstable angina or stable angina, but it is not predictive shortly after acute myocardial infarction.</p><p>Nikfardjam et al.<sup><xref rid="b25-kjim-18-1-29-5" ref-type="bibr">25</xref>)</sup> reported that high CRP level was associated with increased 3-year mortality, but there was only a weak and non-significant association between increased serum CRP and the risk of death. Walter et al.<sup><xref rid="b26-kjim-18-1-29-5" ref-type="bibr">26</xref>)</sup> reported that high CRP level was independently associated with a high risk of adverse coronary events and that restenosis rates were significantly higher in the two upper tertiles compared with CRP levels in the lowest tertiles. Abdelmouttaleb et al.<sup><xref rid="b27-kjim-18-1-29-5" ref-type="bibr">27</xref>)</sup> analyzed 201 patients who underwent diagnostic coronary angiography, 142 patients with coronary artery stenosis, 37 patients without lesions and 37 controls. The serum level of the CRP was closely related to the acute coronary syndrome. Tomoda et al.<sup><xref rid="b21-kjim-18-1-29-5" ref-type="bibr">21</xref>)</sup> reported that CRP was the only prognostic factor in patients with an acute myocardial infarction for the prediction of major adverse cardiac events (MACE), such as recurrent myocardial infarction, target lesion revascularization due to restenosis and cardiac death. Anzai et al.<sup><xref rid="b28-kjim-18-1-29-5" ref-type="bibr">28</xref>)</sup> reported that a peak CRP level of more than 2.0 mg/dL and an age greater than 70 years old were predictive factors for MACE during a one-year clinical follow-up. Giannitsis et al.<sup><xref rid="b29-kjim-18-1-29-5" ref-type="bibr">29</xref>)</sup> reported that the prognostic factors for long-term cardiac death in patients with an acute myocardial infarction were cardiogenic shock and elderly patients older than 75 year of age.</p><p>However, this was a single center study and the major limitation was the sample size of the number of AMI cases that underwent primary or rescue PCI. Further, patients with cardiogenic shock should be divided into a separate group in future studies with a large number of patients.</p><p>In conclusion, an elevated CRP is an independent prognostic marker in patients with acute myocardial infarction after primary or rescue PCI.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="b1-kjim-18-1-29-5"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grines</surname><given-names>CL</given-names></name><name><surname>Browne</surname><given-names>KF</given-names></name><name><surname>Marco</surname><given-names>J</given-names></name><name><surname>Rothbaum</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>J</given-names></name><name><surname>Overlie</surname><given-names>P</given-names></name><name><surname>Donohue</surname><given-names>B</given-names></name><name><surname>Chelliah</surname><given-names>N</given-names></name><collab>Timmis GC for the Primary Angioplasty in Myocardial Infarction Study Group</collab></person-group><article-title>A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction</article-title><source>N Engl J Med</source><volume>28</volume><fpage>673</fpage><lpage>679</lpage><year>1993</year><pub-id pub-id-type="pmid">8433725</pub-id></element-citation></ref><ref id="b2-kjim-18-1-29-5"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Brodie</surname><given-names>BR</given-names></name><name><surname>Griffin</surname><given-names>JJ</given-names></name><name><surname>Costantini</surname><given-names>C</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>St Goar</surname><given-names>FG</given-names></name><name><surname>Overlie</surname><given-names>PA</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>McDonnell</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>WW</given-names></name><collab>Grines CL for the PAMI Stent Pilot Trial Investigators</collab></person-group><article-title>Clinical and angiographic follow-up after primary stenting in acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial</article-title><source>Circulation</source><volume>99</volume><fpage>1548</fpage><lpage>1554</lpage><year>1999</year><pub-id pub-id-type="pmid">10096929</pub-id></element-citation></ref><ref id="b3-kjim-18-1-29-5"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Wal</surname><given-names>AC</given-names></name><name><surname>Becker</surname><given-names>AE</given-names></name><name><surname>van der Loos</surname><given-names>CM</given-names></name><name><surname>Das</surname><given-names>PK</given-names></name></person-group><article-title>Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology</article-title><source>Circulation</source><volume>89</volume><fpage>36</fpage><lpage>44</lpage><year>1994</year><pub-id pub-id-type="pmid">8281670</pub-id></element-citation></ref><ref id="b4-kjim-18-1-29-5"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>The pathogenesis of atherosclerosis: a perspective for the 1990s</article-title><source>Nature</source><volume>362</volume><fpage>801</fpage><year>1993</year><pub-id pub-id-type="pmid">8479518</pub-id></element-citation></ref><ref id="b5-kjim-18-1-29-5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrone</surname><given-names>G</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name><name><surname>Oliviero</surname><given-names>S</given-names></name><name><surname>Arcone</surname><given-names>R</given-names></name><name><surname>Dente</surname><given-names>L</given-names></name><name><surname>Content</surname><given-names>J</given-names></name><name><surname>Cortese</surname><given-names>R</given-names></name></person-group><article-title>Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes</article-title><source>J Biol Chem</source><volume>263</volume><fpage>12554</fpage><lpage>12558</lpage><year>1988</year><pub-id pub-id-type="pmid">2457587</pub-id></element-citation></ref><ref id="b6-kjim-18-1-29-5"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>JM</given-names></name><name><surname>Vilcek</surname><given-names>J</given-names></name></person-group><article-title>Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response</article-title><source>Lab Invest</source><volume>61</volume><fpage>588</fpage><lpage>602</lpage><year>1989</year><pub-id pub-id-type="pmid">2481148</pub-id></element-citation></ref><ref id="b7-kjim-18-1-29-5"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name></person-group><article-title>The acute phase response and C-reactive protein</article-title><person-group person-group-type="editor"><name><surname>Weatherall</surname><given-names>DJ</given-names></name><name><surname>Ledingham</surname><given-names>JGG</given-names></name><name><surname>Warrell</surname><given-names>DA</given-names></name></person-group><source>Oxford textbook of medicine</source><edition>third edition</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name><fpage>1527</fpage><year>1995</year></element-citation></ref><ref id="b8-kjim-18-1-29-5"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>J</given-names></name><name><surname>Schulte</surname><given-names>H</given-names></name><name><surname>Schonfeld</surname><given-names>R</given-names></name><name><surname>Kohler</surname><given-names>E</given-names></name><name><surname>Assmann</surname><given-names>G</given-names></name></person-group><article-title>Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain</article-title><source>Thromb Haemost</source><volume>73</volume><fpage>374</fpage><lpage>379</lpage><year>1995</year><pub-id pub-id-type="pmid">7667818</pub-id></element-citation></ref><ref id="b9-kjim-18-1-29-5"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Kienast</surname><given-names>J</given-names></name><name><surname>Pyke</surname><given-names>SD</given-names></name><name><surname>Haverkate</surname><given-names>F</given-names></name><name><surname>van de Loo</surname><given-names>JC</given-names></name></person-group><article-title>Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris</article-title><source>N Engl J Med</source><volume>332</volume><fpage>635</fpage><lpage>641</lpage><year>1995</year><pub-id pub-id-type="pmid">7845427</pub-id></element-citation></ref><ref id="b10-kjim-18-1-29-5"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Shaten</surname><given-names>J</given-names></name><name><surname>Meilahn</surname><given-names>EN</given-names></name></person-group><article-title>Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study</article-title><source>Am J Epidemiol</source><volume>144</volume><fpage>537</fpage><lpage>547</lpage><year>1996</year><pub-id pub-id-type="pmid">8797513</pub-id></element-citation></ref><ref id="b11-kjim-18-1-29-5"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austen</surname><given-names>WG</given-names></name><name><surname>Edwards</surname><given-names>JE</given-names></name><name><surname>Frye</surname><given-names>RL</given-names></name><name><surname>Gensini</surname><given-names>GG</given-names></name><name><surname>Gott</surname><given-names>VL</given-names></name><name><surname>Griffith</surname><given-names>LS</given-names></name><name><surname>McGoon</surname><given-names>DC</given-names></name><name><surname>Murphy</surname><given-names>ML</given-names></name><name><surname>Roe</surname><given-names>BB</given-names></name></person-group><article-title>A reporting system on patients evaluated for coronary artery disease</article-title><source>Circulation</source><volume>51</volume><fpage>7</fpage><lpage>40</lpage><year>1975</year></element-citation></ref><ref id="b12-kjim-18-1-29-5"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Daley</surname><given-names>WL</given-names></name><name><surname>Dodge</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Alexander</surname><given-names>B</given-names><suffix>Jr</suffix></name><name><surname>Marble</surname><given-names>SJ</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><name><surname>Raymond</surname><given-names>L</given-names></name><name><surname>Fortin</surname><given-names>T</given-names></name><name><surname>Poole</surname><given-names>WK</given-names></name><collab>Braunwald E for the TIMI 4 study group</collab></person-group><article-title>TIMI frame count: a quantitative method of assessing coronary artery flow</article-title><source>Circulation</source><volume>93</volume><fpage>879</fpage><lpage>888</lpage><year>1996</year><pub-id pub-id-type="pmid">8598078</pub-id></element-citation></ref><ref id="b13-kjim-18-1-29-5"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The TIMI Study Group</collab></person-group><article-title>The thrombolysis in myocardial infarction trial</article-title><source>N Engl J Med</source><volume>312</volume><fpage>932</fpage><lpage>936</lpage><year>1985</year><pub-id pub-id-type="pmid">4038784</pub-id></element-citation></ref><ref id="b14-kjim-18-1-29-5"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>JL</given-names></name><name><surname>Saldeen</surname><given-names>TGP</given-names></name><name><surname>Rand</surname><given-names>K</given-names></name></person-group><article-title>Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease</article-title><source>J Am Coll Cardiol</source><volume>31</volume><fpage>1217</fpage><lpage>1225</lpage><year>1998</year><pub-id pub-id-type="pmid">9581711</pub-id></element-citation></ref><ref id="b15-kjim-18-1-29-5"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voulgari</surname><given-names>F</given-names></name><name><surname>Cummins</surname><given-names>P</given-names></name><name><surname>Gardecki</surname><given-names>TI</given-names></name><name><surname>Beeching</surname><given-names>NJ</given-names></name><name><surname>Stone</surname><given-names>PC</given-names></name><name><surname>Stuart</surname><given-names>J</given-names></name></person-group><article-title>Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery and infection</article-title><source>Br Heart J</source><volume>48</volume><fpage>352</fpage><lpage>356</lpage><year>1982</year><pub-id pub-id-type="pmid">6181800</pub-id></element-citation></ref><ref id="b16-kjim-18-1-29-5"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gram</surname><given-names>J</given-names></name><name><surname>Kluft</surname><given-names>C</given-names></name><name><surname>Jespersen</surname><given-names>J</given-names></name></person-group><article-title>Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI)</article-title><source>Thromb Haemost</source><volume>58</volume><fpage>817</fpage><lpage>821</lpage><year>1987</year><pub-id pub-id-type="pmid">2448888</pub-id></element-citation></ref><ref id="b17-kjim-18-1-29-5"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Tambs</surname><given-names>KE</given-names></name><name><surname>Myreng</surname><given-names>Y</given-names></name><name><surname>Engebresten</surname><given-names>LF</given-names></name></person-group><article-title>Acute phase reactants and complement activation in patients with acute myocardial infarction (AMD</article-title><source>Comple- ment</source><volume>5</volume><fpage>33</fpage><lpage>39</lpage><year>1988</year></element-citation></ref><ref id="b18-kjim-18-1-29-5"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>M</given-names></name><name><surname>Haq</surname><given-names>S</given-names></name><name><surname>Tutt</surname><given-names>P</given-names></name><name><surname>Crook</surname><given-names>M</given-names></name></person-group><article-title>Serum total sialic acid and lipid-associated sialic acid in normal individuals and patients with myocardial infarction, and their relationship to acute phase proteins</article-title><source>Ann Clin Biochem</source><volume>30</volume><fpage>383</fpage><lpage>386</lpage><year>1993</year><pub-id pub-id-type="pmid">7691040</pub-id></element-citation></ref><ref id="b19-kjim-18-1-29-5"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Interleukin-6 and the pathogenesis of the acute-phase response</article-title><source>N Engl J Med</source><volume>311</volume><fpage>1413</fpage><year>1984</year><pub-id pub-id-type="pmid">6208485</pub-id></element-citation></ref><ref id="b20-kjim-18-1-29-5"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyao</surname><given-names>Y</given-names></name><name><surname>Yasue</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Misumi</surname><given-names>I</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>E</given-names></name></person-group><article-title>Elevated plasma interleukin-6 level in patients with acute myocardial infarction</article-title><source>Am Heart J</source><volume>126</volume><fpage>1299</fpage><lpage>1304</lpage><year>1993</year><pub-id pub-id-type="pmid">8249785</pub-id></element-citation></ref><ref id="b21-kjim-18-1-29-5"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomoda</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>N</given-names></name></person-group><article-title>Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction</article-title><source>Am Heart J</source><volume>140</volume><fpage>324</fpage><year>2000</year><pub-id pub-id-type="pmid">10925350</pub-id></element-citation></ref><ref id="b22-kjim-18-1-29-5"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Jeong</surname><given-names>MH</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Joo</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JC</given-names></name><name><surname>Ahn</surname><given-names>YK</given-names></name><name><surname>Na</surname><given-names>KJ</given-names></name><name><surname>Cho</surname><given-names>JG</given-names></name><name><surname>Ahn</surname><given-names>BH</given-names></name><name><surname>Park</surname><given-names>JC</given-names></name><name><surname>Kang</surname><given-names>JC</given-names></name></person-group><article-title>The role of chronic infection and inflammation to coronary artery disease in Korean patients with coronary artery disease</article-title><source>Korean Circulation J</source><volume>30</volume><fpage>1107</fpage><lpage>1116</lpage><year>2000</year></element-citation></ref><ref id="b23-kjim-18-1-29-5"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>Buffon</surname><given-names>A</given-names></name><name><surname>Biasucci</surname><given-names>LM</given-names></name><name><surname>Gallimore</surname><given-names>JR</given-names></name><name><surname>Caligiuri</surname><given-names>G</given-names></name><name><surname>Vitelli</surname><given-names>A</given-names></name><name><surname>Altamura</surname><given-names>S</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name><name><surname>Rebuzzi</surname><given-names>AG</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina</article-title><source>Circulation</source><volume>98</volume><fpage>2370</fpage><lpage>2376</lpage><year>1998</year><pub-id pub-id-type="pmid">9832480</pub-id></element-citation></ref><ref id="b24-kjim-18-1-29-5"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zebrack</surname><given-names>JS</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Maycock</surname><given-names>CA</given-names></name><name><surname>Horne</surname><given-names>BD</given-names></name><name><surname>Bair</surname><given-names>TL</given-names></name><name><surname>Muhlestein</surname><given-names>JB</given-names></name><collab>The Intermountain Heart Collaborative (IHC) Study Group</collab></person-group><article-title>Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction</article-title><source>Am J Cardiol</source><volume>89</volume><fpage>145</fpage><lpage>149</lpage><year>2002</year><pub-id pub-id-type="pmid">11792332</pub-id></element-citation></ref><ref id="b25-kjim-18-1-29-5"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikfardjam</surname><given-names>M</given-names></name><name><surname>Mullner</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>W</given-names></name><name><surname>Oschatz</surname><given-names>E</given-names></name><name><surname>Exner</surname><given-names>M</given-names></name><name><surname>Domanovits</surname><given-names>H</given-names></name><name><surname>Laggner</surname><given-names>AN</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name></person-group><article-title>The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction</article-title><source>J Intern Med</source><volume>247</volume><fpage>341</fpage><lpage>345</lpage><year>2000</year><pub-id pub-id-type="pmid">10762450</pub-id></element-citation></ref><ref id="b26-kjim-18-1-29-5"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>DH</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Sellwig</surname><given-names>M</given-names></name><name><surname>Auch-Schwelk</surname><given-names>W</given-names></name><name><surname>Schachinger</surname><given-names>V</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group><article-title>Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation</article-title><source>J Am Coll Cardiol</source><volume>37</volume><fpage>839</fpage><lpage>846</lpage><year>2001</year><pub-id pub-id-type="pmid">11693760</pub-id></element-citation></ref><ref id="b27-kjim-18-1-29-5"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelmouttaleb</surname><given-names>I</given-names></name><name><surname>Danchin</surname><given-names>N</given-names></name><name><surname>Ilardo</surname><given-names>C</given-names></name><name><surname>Aimone-Gastin</surname><given-names>I</given-names></name><name><surname>Angioi</surname><given-names>M</given-names></name><name><surname>Lozniewski</surname><given-names>A</given-names></name><name><surname>Loubinoux</surname><given-names>J</given-names></name><name><surname>Le Faou</surname><given-names>A</given-names></name><name><surname>Gueant</surname><given-names>JL</given-names></name></person-group><article-title>C-reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes</article-title><source>Am Heart J</source><volume>137</volume><fpage>346</fpage><lpage>351</lpage><year>1999</year><pub-id pub-id-type="pmid">9924170</pub-id></element-citation></ref><ref id="b28-kjim-18-1-29-5"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannitsis</surname><given-names>E</given-names></name><name><surname>Lehrke</surname><given-names>S</given-names></name><name><surname>Wiegand</surname><given-names>UK</given-names></name><name><surname>Kurwski</surname><given-names>J</given-names></name><name><surname>Muller-Bardorff</surname><given-names>M</given-names></name><name><surname>Weidtman</surname><given-names>B</given-names></name><name><surname>Richardt</surname><given-names>G</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><name><surname>Anzai</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Shiraki</surname><given-names>H</given-names></name><name><surname>Asakura</surname><given-names>Y</given-names></name><name><surname>Akaishi</surname><given-names>M</given-names></name><name><surname>Mitamura</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><article-title>C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction</article-title><source>Circulation</source><volume>96</volume><fpage>778</fpage><lpage>784</lpage><year>1997</year><pub-id pub-id-type="pmid">9264482</pub-id></element-citation></ref><ref id="b29-kjim-18-1-29-5"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannitsis</surname><given-names>E</given-names></name><name><surname>Lehrke</surname><given-names>S</given-names></name><name><surname>Wiegand</surname><given-names>UK</given-names></name><name><surname>Kurowski</surname><given-names>J</given-names></name><name><surname>Muller-Bardoff</surname><given-names>M</given-names></name><name><surname>Weidtmann</surname><given-names>B</given-names></name><name><surname>Richardt</surname><given-names>G</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name></person-group><article-title>Risk stratification in patients with inferior acute myocardial infarction treated by percutaneous coronary intervention: The role of admission troponin-T</article-title><source>Circulation</source><volume>102</volume><fpage>2038</fpage><lpage>2044</lpage><year>2000</year><pub-id pub-id-type="pmid">11044417</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group I<break/>(n=86)</th><th align="center" valign="top" rowspan="1" colspan="1">Group II<break/>(n=122)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43&#x000b1;0.14</td><td align="center" valign="top" rowspan="1" colspan="1">3.50&#x000b1;1.93</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (yr)</td><td align="center" valign="top" rowspan="1" colspan="1">59.9&#x000b1;9.3</td><td align="center" valign="top" rowspan="1" colspan="1">59.1&#x000b1;10.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male (%)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (74.4)</td><td align="center" valign="top" rowspan="1" colspan="1">102 (83.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.104</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Risk factors (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">31 (36.0)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (41.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.472</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">16 (18.6)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.373</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking</td><td align="center" valign="top" rowspan="1" colspan="1">38 (44.2)</td><td align="center" valign="top" rowspan="1" colspan="1">62 (50.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.346</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">hyperlipidemia</td><td align="center" valign="top" rowspan="1" colspan="1">31 (36.0)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Troponin-I (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">20.6&#x000b1;37.7</td><td align="center" valign="top" rowspan="1" colspan="1">79.2&#x000b1;70.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Troponin-T (ng/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55&#x000b1;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">2.87&#x000b1;2.40</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESR (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">9.9&#x000b1;12.6</td><td align="center" valign="top" rowspan="1" colspan="1">16.7&#x000b1;27.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shock on admission (%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (12.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline ejection fraction (%)</td><td align="center" valign="top" rowspan="1" colspan="1">49.4&#x000b1;10.5</td><td align="center" valign="top" rowspan="1" colspan="1">50.1&#x000b1;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.673</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Percutaneous coronary intervention (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rescue PCI</td><td align="center" valign="top" rowspan="1" colspan="1">12 (14.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (15.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary PCI</td><td align="center" valign="top" rowspan="1" colspan="1">74 (86.0)</td><td align="center" valign="top" rowspan="1" colspan="1">103 (84.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Time from pain to admission (min)</td><td align="center" valign="bottom" rowspan="1" colspan="1">195&#x000b1;120</td><td align="center" valign="bottom" rowspan="1" colspan="1">200&#x000b1;117</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.860</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time from pain to PCI (min)</td><td align="center" valign="top" rowspan="1" colspan="1">278&#x000b1;99</td><td align="center" valign="top" rowspan="1" colspan="1">282&#x000b1;101</td><td align="center" valign="top" rowspan="1" colspan="1">0.843</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-kjim-18-1-29-5"><p>CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PCI, percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Coronary angiographic findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group I<break/>(n=86)</th><th align="center" valign="top" rowspan="1" colspan="1">Group II<break/>(n=122)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of involved vessels (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;One</td><td align="center" valign="top" rowspan="1" colspan="1">45 (52.3)</td><td align="center" valign="top" rowspan="1" colspan="1">70 (57.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Two</td><td align="center" valign="top" rowspan="1" colspan="1">30 (34.9)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (30.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Three</td><td align="center" valign="top" rowspan="1" colspan="1">11 (12.8)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (12.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean No.</td><td align="center" valign="top" rowspan="1" colspan="1">1.60&#x000b1;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">1.54&#x000b1;0.71</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Target coronary artery (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.642</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Left anterior descending artery</td><td align="center" valign="top" rowspan="1" colspan="1">41 (47.7)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (52.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Left circumflex artery</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Right coronary artery</td><td align="center" valign="top" rowspan="1" colspan="1">40 (46.5)</td><td align="center" valign="top" rowspan="1" colspan="1">49 (40.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACC/AHA classification (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type A</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type B<sub>1</sub></td><td align="center" valign="top" rowspan="1" colspan="1">41 (47.7)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (52.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type B<sub>2</sub></td><td align="center" valign="top" rowspan="1" colspan="1">19 (22.1)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (18.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Type C</td><td align="center" valign="top" rowspan="1" colspan="1">24 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intra-coronary thrombosis (%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (18.6)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (23.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TIM I flow (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.087</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;0</td><td align="center" valign="top" rowspan="1" colspan="1">24 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (29.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (5.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;2</td><td align="center" valign="top" rowspan="1" colspan="1">29 (33.7)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (45.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3</td><td align="center" valign="top" rowspan="1" colspan="1">20 (23.3)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (19.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean TIMI flow</td><td align="center" valign="top" rowspan="1" colspan="1">1.28&#x000b1;0.82</td><td align="center" valign="top" rowspan="1" colspan="1">0.92&#x000b1;1.04</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn2-kjim-18-1-29-5"><p>ACC/AHA, American College of Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarction</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Results after percutaenous coronary intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group I<break/>(n=86)</th><th align="center" valign="top" rowspan="1" colspan="1">Group II<break/>(n=122)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Post-PCI TIMI flow (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.863</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;0</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;2</td><td align="center" valign="top" rowspan="1" colspan="1">10 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3</td><td align="center" valign="top" rowspan="1" colspan="1">71 (82.6)</td><td align="center" valign="top" rowspan="1" colspan="1">99 (81.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean TIMI flow</td><td align="center" valign="top" rowspan="1" colspan="1">2.77&#x000b1;0.55</td><td align="center" valign="top" rowspan="1" colspan="1">2.77&#x000b1;0.53</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary success rate (%)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (94.2)</td><td align="center" valign="top" rowspan="1" colspan="1">116 (95.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ejection fraction after PCI (%)</td><td align="center" valign="top" rowspan="1" colspan="1">52.0&#x000b1;9.0</td><td align="center" valign="top" rowspan="1" colspan="1">52.7&#x000b1;9.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.553</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Survival (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1 month</td><td align="center" valign="top" rowspan="1" colspan="1">84 (97.7)</td><td align="center" valign="top" rowspan="1" colspan="1">112 (91.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;6 months</td><td align="center" valign="top" rowspan="1" colspan="1">84 (97.7)</td><td align="center" valign="top" rowspan="1" colspan="1">111 (91.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;12 months</td><td align="center" valign="top" rowspan="1" colspan="1">83 (96.5)</td><td align="center" valign="top" rowspan="1" colspan="1">106 (86.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-kjim-18-1-29-5"><p>TIMI, Thrombolysis In Myocardial Infarction; PCI, percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Improvement of the ejection fraction and Thrombolysis In Myocardial Infarction flow after percutaneous coronary intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">EF (%)</th><th align="center" valign="top" rowspan="1" colspan="1">EF after PCI (%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Normal CRP (n=86)</td><td align="center" valign="top" rowspan="1" colspan="1">49.4&#x000b1;10.5</td><td align="center" valign="top" rowspan="1" colspan="1">52.0&#x000b1;9.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High CRP (n=122)</td><td align="center" valign="top" rowspan="1" colspan="1">50.1&#x000b1;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">52.7&#x000b1;9.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">TIMI</td><td align="center" valign="top" rowspan="1" colspan="1">TIMI after PCI</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Normal CRP (n=86)</td><td align="center" valign="top" rowspan="1" colspan="1">1.52&#x000b1;1.13</td><td align="center" valign="top" rowspan="1" colspan="1">2.77&#x000b1;0.55</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High CRP (n=122)</td><td align="center" valign="top" rowspan="1" colspan="1">1.55&#x000b1;1.11</td><td align="center" valign="top" rowspan="1" colspan="1">2.76&#x000b1;0.53</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-kjim-18-1-29-5"><p>EF, ejection fraction; PCI, percutaneous coronary intervention; CRP, C-reactive protein; TIMI, Thrombolysis In Myocardial Infarction</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Adverse clinical events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group I<break/>(n=86)</th><th align="center" valign="top" rowspan="1" colspan="1">Group II<break/>(n=122)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">In-hospital events (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Reinfarction</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.687</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Target vessel revascularization</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Death</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;MACE</td><td align="center" valign="top" rowspan="1" colspan="1">8 (9.3)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (18.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.021</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Follow-up events at 1 year (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Restenosis</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (28.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Target vessel revascularization</td><td align="center" valign="top" rowspan="1" colspan="1">10 (11.6)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (23.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Death</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (13.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-kjim-18-1-29-5"><p>MACE, major adverse cardiac events</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-kjim-18-1-29-5" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Multiple logistic regression analysis for the prediction of the one-year mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">Odds ratio</th><th align="center" valign="top" rowspan="1" colspan="1">95% Cl</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiogenic shock</td><td align="center" valign="top" rowspan="1" colspan="1">9.11</td><td align="center" valign="top" rowspan="1" colspan="1">4.10&#x02013;30.67</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP on admission</td><td align="center" valign="top" rowspan="1" colspan="1">8.21</td><td align="center" valign="top" rowspan="1" colspan="1">2.54&#x02013;20.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Post-PCI EF</td><td align="center" valign="top" rowspan="1" colspan="1">4.65</td><td align="center" valign="top" rowspan="1" colspan="1">1.70&#x02013;10.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Admission cTnT (&#x02265;0.1 vs &#x0003c;0.1 ng/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">4.49</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#x02013;10.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">2.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.30&#x02013;10.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.287</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Target artery</td><td align="center" valign="top" rowspan="1" colspan="1">1.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.52&#x02013;2.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.511</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No. of vessels involved</td><td align="center" valign="top" rowspan="1" colspan="1">1.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.51&#x02013;4.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.409</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Initial TIMI flow</td><td align="center" valign="top" rowspan="1" colspan="1">1.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.59&#x02013;3.81</td><td align="center" valign="top" rowspan="1" colspan="1">0.267</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Post-PCI TIMI flow</td><td align="center" valign="top" rowspan="1" colspan="1">1.91</td><td align="center" valign="top" rowspan="1" colspan="1">0.56&#x02013;7.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.308</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Initial ejection fraction</td><td align="center" valign="top" rowspan="1" colspan="1">1.13</td><td align="center" valign="top" rowspan="1" colspan="1">1.0 &#x02013;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-kjim-18-1-29-5"><p>CRP, C-reactive protein; PCI, percutaneous coronary intervention; EF, ejection fraction; cTnT, cardiac troponin-T; TIMI, Thrombolysis In Myocardial infarction</p></fn></table-wrap-foot></table-wrap></floats-group></article>